Comparing SG&A Expenses: Viatris Inc. vs Agios Pharmaceuticals, Inc. Trends and Insights

SG&A Expenses: Viatris vs Agios - A Decade of Change

__timestampAgios Pharmaceuticals, Inc.Viatris Inc.
Wednesday, January 1, 2014191200001499100000
Thursday, January 1, 2015359920001923500000
Friday, January 1, 2016507140002351400000
Sunday, January 1, 2017711240002564000000
Monday, January 1, 20181141450002397300000
Tuesday, January 1, 20191320340002503400000
Wednesday, January 1, 20201490700003344600000
Friday, January 1, 20211214450004529200000
Saturday, January 1, 20221216730004179100000
Sunday, January 1, 20231199030004650100000
Monday, January 1, 2024156784000
Loading chart...

Unveiling the hidden dimensions of data

SG&A Expenses: A Tale of Two Companies

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Viatris Inc. and Agios Pharmaceuticals, Inc. over the past decade.

Viatris Inc.: A Steady Climb

Viatris Inc. has shown a consistent increase in SG&A expenses, peaking in 2023 with a staggering 210% rise from 2014. This growth reflects the company's expansive strategies and market penetration efforts.

Agios Pharmaceuticals, Inc.: A Modest Growth

In contrast, Agios Pharmaceuticals, Inc. experienced a more modest increase, with expenses growing by approximately 525% over the same period. This indicates a more conservative approach, focusing on sustainable growth.

Insights and Implications

These trends highlight the differing strategies of these companies, offering insights into their operational priorities and market strategies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025